Schizophrenia Trial, Recruiting NCT06642675 Sponsor: Central South University Condition: Schizophrenia
Back to Schizophrenia

Schizophrenia Trial, Recruiting

NCT06642675
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with schizophrenia based on recognised international medical guidelines (ICD-11).
  • Your diagnosis of schizophrenia has been confirmed through a structured research interview (a formal set of questions used to check the diagnosis).
  • You show notable "negative symptoms" of schizophrenia — such as reduced emotion, motivation, or speech — rated above a certain level on a standard assessment scale (confirm with trial site).
  • You are under 60 years of age.

Who may not be able to join:

  • You have been diagnosed with certain other conditions, such as bipolar disorder, neurodevelopmental disorders, or drug use disorders (note: alcohol and tobacco use are not excluded).
  • You have a serious or sudden physical illness, such as a recent brain injury, serious heart or lung condition, blood disorder, or an infection affecting the brain.
  • You have a clearly identified genetic condition, such as tuberous sclerosis, multiple sclerosis, or certain chromosomal syndromes (confirm with trial site for the full list).
  • You cannot safely have an MRI scan or a type of brain stimulation treatment called rTMS — for example, because you have metal implants in your body, a history of epilepsy, or a cochlear implant.
  • You are considered to be at serious risk of harming yourself or attempting suicide.
  • The research team decides for any other reason that participation would not be appropriate for you.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Renrong Wu, M.D., Ph.D., Mental Health Institute of Second Xiangya Hospital,CSU

Phone: 15874179855

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Central South University
Registry
ClinicalTrials.gov
Start date
22 November 2024
Est. completion
1 February 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Change in Positive and Negative Symptom Scale (PANSS) score; Change in Scale for Assessment of Negative Symptoms(SANS) score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov